Lugano, Switzerland, 13 October 2025 – The ESMO Congress 2025 will take place from 17-21 October in Berlin, Germany, where internationally renowned oncology experts will present cutting-edge data and engage in thought-provoking discussions covering the current advances and future directions of oncology research and care.
The congress will take place both onsite and remotely. Within a programme covering 5 days (accessible here), below are some of the most interesting topics that will be presented and discussed:
-
Advancing precision oncology through biomarkers and AI, with data examining approaches to optimise and predict immunotherapy responses across cancer settings (abstracts 110O, 111O, 112O, 108O), on applying AI to refine clinical trial design and treatment comparisons (3136O).
-
Antibody-drug conjugates (ADCs) in breast cancer and other tumours, including data on trastuzumab deruxtecan (T-DXd) in early breast cancer (291O, LBA1). Additional studies explore first-line options in triple-negative breast cancer (LBA20, LBA22). Promising Phase-3 studies on ADCs in bladder cancer (LBA2) and lung cancer (LBA5). Saturday’s Keynote lecture will address the early and late spectrum of development of ADCs combinations.
-
Dose optimisation strategies to improve patient's outcomes: Data with the potential of ctDNA to guide optimisation approaches in colon cancer (LBA9) and urothelial cancer (LBA109), and to help avoid overtreatment in bladder cancer (LBA8).
-
New treatment modalities, and vaccines in melanoma, including an early-phase trial investigating cell therapy in a rare subtype (1600O), data on personalised vaccines in advanced disease, especially for patients with limited response to current therapies or lacking key immune markers (1516MO, LBA53). Clinical perspectives on therapeutic vaccines will be the focus of Sunday’s Keynote Lecture.
-
Novel treatment combinations in genitourinary cancers, with data from Phase-3 trials that may influence clinical practice in urothelial carcinoma (LBA7) and prostate cancer (LBA6).
-
Immunotherapy-based approaches across cancer settings, including data investigating a potential new treatment option for a type of ovarian cancer where therapeutic choices remain limited (LBA3). Findings examine immunotherapy combinations as potential first-line treatment in lung cancer (LBA4), while new evidence comes for targeted immunotherapy in gastric cancer (LBA10). Novel data in triple negative breast cancers further explore the role of immune-based strategies in enhancing response to standard treatment (LBA15).
The ESMO 2025 Opening Press Conference, Friday, 17 October (10:30-11:15 CEST), will feature insights from:
-
Fabrice André, Insititute Gustave Roussy Department of Medical Oncology, Villejuif, France – ESMO President
-
Myriam Chalabi, Netherlands Cancer Institute, Amsterdam, Netherlands – ESMO 2025 Scientific Co-Chair
Press Briefings will take place during the congress days: Saturday, Sunday, Monday,12:30-13:15 CEST.
Details about the press conferences will be published here. All press events will be held onsite, with a virtual participation option available. Please, note that press accreditation is required to attend.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for the ESMO Congress 2025. To apply for press accreditation, please fill out the form available here.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press, must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
Further information
ESMO Press Office
press@esmo.org